Home Daily Intelligence Tracker
    • Plans Blog Contact
    Agios Pharm logo
    AGIO

    Agios Pharm

    MaveScore 36 Low model confidence
    Last Price US$41.23 As of Jul 10, 2026
    Market Cap US$2.4b Company size context
    7D Performance 9.71% Past 7 days
    1Y Performance 4.35% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 36 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    13/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    6/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    4/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    12/15 Strong

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    1/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    • Highlights research candidates with supportive 3-month and 6-month price regimes.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Agios Pharm Overview

    Industry: Biotechnology

    Sector: Healthcare

    Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; a Read More

    Agios Pharm is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Agios Pharm

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 29, 2026

    Quarterly result summary

    Revenue was $20.7M (+138% YoY). Net loss was -$99.1M (from $89.3M). R&D expense was $81.1M.

    Revenue $20.7M +138% YoY
    Net loss -$99.1M from $89.3M
    R&D expense $81.1M reported
    Cash $1B reported

    What changed

    • Revenue +138% YoY to $20.7M.
    • Net loss was -$99.1M (from $89.3M).

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K Apr 29, 2026 SEC filing 10-Q Apr 29, 2026 SEC filing 10-K Feb 12, 2026 SEC filing 8-K Feb 12, 2026 Earnings release Earnings release Feb 12, 2026 SEC filing 8-K Oct 30, 2025 Earnings release Earnings release Oct 30, 2025 SEC filing 10-Q Oct 30, 2025 SEC filing 8-K Jul 31, 2025 Earnings release Earnings release Jul 31, 2025 SEC filing 10-Q Jul 31, 2025

    Recent News



    Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target
    Tue, 07 Jul 2026 19:35:01 GMT
    Why Is Agios Pharma Stock Soaring Tuesday?
    Tue, 07 Jul 2026 18:27:54 GMT
    Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
    Tue, 07 Jul 2026 16:59:27 GMT

    Earnings Per Share

    Score 3.00/5
    Agios Pharm boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.77/5
    Agios Pharm exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Agios Pharm AGIO US$2.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.76/5
    Agios Pharm olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Agios Pharm AGIO US$2.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.71/5
    Agios Pharm attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Agios Pharm AGIO US$2.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Agios Pharm logo

    Agios Pharm

    US$41.23

    US$2.4b

    9.71%

    4.35%